Pacific Biosciences of California (PACB) 2021年年度报告「NASDAQ」.pdf

1、2021 ANNUAL REPORTFellow Stockholders,On behalf of the Board and our employees,thank you for your investment and continued support in PacBio.At PacBio,our focus is centered on creating the worlds most advanced sequencing technologies so we can realize our mission of enabling the promise of genomics

2、to better human health.We believe that by offering researchers products that enable a more complete and accurate view of the genome,we can allow them to tackle some of the worlds most complex genetic challenges.Reflecting on 2021 In 2021,we continued our transformation of PacBio to better serve our

3、customers and,in turn,drive long-term stockholder value.Our strategy included expanding our commercial reach,driving product development,and demonstrating leadership in clinical whole-genome sequencing.While we enjoyed many successes in 2021,such as record annual revenue and system placements,it was

4、 only an initial step toward realizing our mission.We continued to build a best-in-class team,doubling our quota-carrying sales representatives and growing and reinvigorating our R&D organization.Our clinical research collaborations bore tangible results as well.For example,Childrens Mercy Kansas Ci

5、ty showed that PacBio sequencing yielded a more than 4-fold increase in the discovery rate of rare coding structural variants relative to short-read technology,and Rady Childrens Institute for Genomic Medicine cited long-read sequencings ability to detect numerous variants not readily detectible by

6、short-read sequencing.We believe proof points like these and others will continue to fuel the adoption of PacBio long-read sequencing when we launch even higher throughput products and serve as steppingstones toward ultimately seeing the adoption of long-read sequencing in many clinical settings.Cre